Laurion Capital Management LP Eiger Bio Pharmaceuticals, Inc. Transaction History

Laurion Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$6.68 - $9.1 $487,139 - $663,617	-72,925 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$7.82 - $9.23 $857,908 - $1.01 Million	-109,707 Reduced 60.07%	72,925 $621,000
Q1 2021 May 14, 2021	SELL	$8.44 - $12.66 $585,136 - $877,705	-69,329 Reduced 27.52%	182,632 $1.62 Million
Q4 2020 Feb 12, 2021	BUY	$7.98 - $12.29 $2.01 Million - $3.1 Million	251,961 New	251,961 $3.1 Million
Q2 2019 Aug 13, 2019	SELL	$9.54 - $14.96 $1.09 Million - $1.71 Million	-114,038 Closed	0 $0

Q1 2019 May 08, 2019	BUY	$10.31 - $14.38 $656,705 - $915,948	63,696 Added 126.53%	114,038 $1.59 Million
Q4 2018 Feb 14, 2019	BUY	$8.63 - $12.4 $434,451 - $624,240	50,342 New	50,342 $511,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $496M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.